Meadowbrook Advisors Group LLC Makes New Investment in Amgen Inc. $AMGN

Meadowbrook Advisors Group LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 6,416 shares of the medical research company’s stock, valued at approximately $2,100,000. Amgen comprises about 1.2% of Meadowbrook Advisors Group LLC’s investment portfolio, making the stock its 27th biggest holding.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Anfield Capital Management LLC raised its holdings in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the period. Dogwood Wealth Management LLC grew its holdings in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the period. Board of the Pension Protection Fund acquired a new position in Amgen during the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC increased its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new stake in Amgen in the fourth quarter valued at approximately $33,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $337.60 on Friday. The firm has a market cap of $182.21 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The business’s 50 day moving average is $340.71 and its 200-day moving average is $345.76. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the company posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.

Analysts Set New Price Targets

AMGN has been the topic of a number of recent analyst reports. Mizuho boosted their target price on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday. Morgan Stanley raised their price target on Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a report on Tuesday, June 9th. Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Royal Bank Of Canada upped their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Daiwa Securities Group dropped their price objective on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.